1066 (1066) Fair Value & Analysis

Healthcare · Market cap HK$14.4B

1 1066 1066 · HK

PriceHK$3.17

Fair ValueHK$8.17

Upside+157.7%

Quality51/100

Evidence: Medium Range HK$6.30 – HK$10.04

Fair value as of: Jul 2, 2026

From 24 valuation models · updated today

Share price −3.8% over the past month.

Price vs Fair Value (12 months)

12‑month range HK$3.10 – HK$6.94 · fair‑value band HK$6.30 – HK$10.04 · the HK$3.17 price screens below the HK$8.17 fair value. As of Jul 2, 2026.

✦ Which stocks are undervalued right now? Check free Discover now →

Analysis

1066 (1066) currently trades at HK$3.17, while our model-based Fair Value estimate is HK$8.17 — implying the stock looks roughly 157.7% undervalued today. We read business quality at 51/100 (solid quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: medium) — always confirm before acting.

Over the trailing twelve months, 1066 generated revenue of HK$13.4B at a net margin of 12.0%. Revenue grew 4.5% year over year. It earns a return on equity of 6.7%. The balance sheet holds a net cash position of HK$3.0B. Fundamentals as of Jul 2, 2026

Key figures & financial health

Revenue (TTM) HK$13.4B

Revenue growth (YoY) +4.5%

Net margin 12.0%

Return on equity 6.7%

Free cash flow HK$1.7B FY2025

P/E ratio 8.1

More key figures

Operating margin 9.9%

EPS (TTM) HK$0.2200

Dividend yield 5.0%

EPS growth (YoY) -38.1%

Net cash HK$3.0B FY2025

Figures from reported company fundamentals (EODHD) · as of Jul 2, 2026. TTM = trailing twelve months.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

1066 reported revenue of HK$13.4B in FY2025 versus HK$13.2B in FY2021, a compound +0.4%/yr. Reported net income was HK$1.6B in FY2025, compounding −8.3%/yr from FY2021.

Revenue +0.4%/yr

FY21 HK$13.2B

FY22 HK$13.6B

FY23 HK$13.2B

FY24 HK$13.1B

FY25 HK$13.4B

Net income −8.3%/yr

FY21 HK$2.3B

FY22 HK$2.8B

FY23 HK$2.0B

FY24 HK$2.1B

FY25 HK$1.6B

Is 1066 fairly valued? → Check now

Similar stocks

6 more Medical Instruments & Supplies stocks, each showing price versus our Fair Value estimate (as of Jul 2, 2026).

Stock	Price	Fair Value	vs Fair Value
Intuitive Surgical, Inc ISRG	$402.95	$182.39	-55%
EssilorLuxottica Société anonyme ESLOF	$190.25	$125.65	-34%
HOYA Corporation HOCPY	$168.16	$96.16	-43%
Medline Inc MDLN	$33.61	$31.78	-5%
Becton, Dickinson and Company BDX	$149.56	$117.04	-22%
Alcon Inc ALC	$66.11	$36.99	-44%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks Technology Financial Services Healthcare Consumer Cyclical Consumer Defensive Communication Services Industrials Energy Basic Materials Real Estate Utilities Deeply Undervalued Stocks Undervalued Blue-Chip Stocks Undervalued Small-Cap Stocks

Frequently asked questions

Is 1066 (1066) undervalued?

As of Jul 2, 2026, our model estimates a fair value of HK$8.17 versus a price of HK$3.17 — about +158% (undervalued). Model-based estimate, not financial advice.

What is the fair value of 1066?

Our model-based fair value for 1066 is HK$8.17 (as of Jul 2, 2026), built from audited fundamentals. The current price is HK$3.17.

What is the quality score of 1066?

1066 has a Quality Score of 51/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

What is the revenue of 1066 (1066)?

1066 reported trailing-twelve-month revenue of about HK$13.4B (latest available figure, as of Jul 2, 2026).

What is the net profit margin of 1066?

The net profit margin of 1066 is about 12.0%, meaning it keeps roughly 12.0% of revenue as net income. Based on the latest reported figures.

Does 1066 pay a dividend?

1066 currently shows a dividend yield of about 4.95% relative to its recent price (as of Jul 2, 2026).

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.